There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Ultragenyx Pharmaceutical (RARE – Re ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mereo Biopharma Group Plc (MREO – Research Report), Amgen (AMGN – Research Rep ...

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

The placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference ...

A 1‑for‑10 reverse stock split consolidates shares but not value. Learn how it works, why it's done, and see other recent ...

Read about Arrowhead Pharmaceuticals Inc (ARWR:XNAS) stock and today's latest news and financial updates.